Synergistic Targeting of BRCA1 Mutated Breast Cancers with PARP and CDK2 Inhibition

In cell lines, BRCA1 loss was associated with stabilized cyclin E1 during the cell cycle, and BRCA1 siRNA led to increased cyclin E1 in association with reduced phospho-cyclin E1 T62.